HomeNewsBusinessStocksBuy Pidilite, Tata Sponge, Venus Remedies: Manav Chopra
Trending Topics
Sensex Live
Meesho IPO GMP
Exato Technologies IPO Allotment
Aequs IPO GMP
Vidya Wires IPO

Buy Pidilite, Tata Sponge, Venus Remedies: Manav Chopra

Manav Chopra of Nirmal Bang recommends buying Biocon for a target price of Rs 520 and Venus Remedies for a target price of Rs 370.

September 10, 2014 / 12:59 IST
Story continues below Advertisement
Remove Ad

Your browser doesn't support HTML5 video.

In CNBC-TV18's popular show Bull's Eye, Manav Chopra of Nirmal Bang shares his trading strategies for the day.

One can buy Pidilite Industries for a target price of Rs 415 and keep a stoploss at Rs 388.

Story continues below Advertisement
Remove Ad

One can buy Tata Sponge Iron for a target price of Rs 1,080 and keep a stoploss at Rs 915.

One can buy Venus Remedies for a target price of Rs 370 and keep a stoploss at Rs 304.

Follow Us On: Facebook twitter instagram linkedin youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.